explore -WSS

explore

author：fashion 2025-09-07 14:01:00 - browse：3469

An orange Flovent inhaler on a white background. -- health coverage from STAT — Adobe

As of Jan. 1, thousands of asthma patients in the U.S. will no longer be able to get refills for Flovent — one of the most popular inhalers in the U.S. for nearly 30 years.

Flovent’s manufacturer, GSK, has discontinued both versions of the product — Flovent HFA, an inhalation aerosol, and Flovent Diskus, an inhalation powder — and replaced each with what is known as an “authorized generic,” essentially the same product sold under a private label. Prasco, a U.S. drugmaker specializing in authorized generics, will distribute the new inhaler, sold as fluticasone.

The timing of the change is telling: Flovent’s price rose nearly 50% since 2014, according to GoodRx, leaving the drug vulnerable to the new Medicaid penalties going into effect as of this year for medications with price increases that outpace inflation. By discontinuing the brand-name inhaler but continuing to earn money from the authorized generic, GSK will be able to avoid paying a penalty.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Humana sues Biden admin over Medicare Advantage audit rule

Wikipedia

WSS

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Illumina names Agilent executive as new CEO

What drug price negotiations mean for Medicare Part D

Covid hospitalizations on the rise, Humana says

What Congress can do to address the rural doctor shortage

Medicaid rebukes states for mistakenly disenrolling children

knowledge

explore

explore

Medicare proposal to cover medical devices draws a mixed reaction

Biotech lab space demand falls sharply

DIEP, the 'gold standard' of breast reconstruction, is under threat

Snackable artificial intelligence, expert AI, and the pharma industry

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Microbiome research is starting to find links to chronic diseases

Drug repurposing or repositioning? The language matters

Microbiome research is starting to find links to chronic diseases

23andMe had bad news about my health. I wish a person had delivered it

The (many) problems with a new study criticizing cancer screening

focus

What drug price negotiations mean for Medicare Part D

Microbiome research is starting to find links to chronic diseases

Stem cell treatment guidelines are released by FDA

Amazon on where the company's health care bets are headed next

AstraZeneca chief proposes a novel edit to the drug pricing bill

Intarcia’s device

Wikipedia

Wikipedia

Wikipedia

hotspot